Preinfection characteristics in the entire cohort
| Characteristic . | All patients . | Not hospitalized . | Hospitalized . | P . | |||
|---|---|---|---|---|---|---|---|
| n . | Results . | n . | Results . | n . | Results . | ||
| Demographic | |||||||
| Age, median (IQR), y | 66 | 34 (24-40) | 16 | 36 (26-40) | 50 | 33 (24-40) | .72 |
| Female sex | 66 | 36 (55) | 16 | 12 (75) | 50 | 24 (48) | .084 |
| Hispanic | 66 | 10 (15) | 16 | 3 (19) | 50 | 7 (14) | .70 |
| Genotype | 66 | 16 | 50 | .79 | |||
| SS/Sβ0 | 47 (71) | 13 (81) | 34 (68) | ||||
| SC | 14 (21) | 2 (13) | 12 (24) | ||||
| Sβ+ | 5 (8) | 1(6) | 4 (8) | ||||
| BMI, median (IQR), kg/m2 | 65 | 24.3 (20.2-27.8) | 16 | 24.4 (19.2-27.2) | 49 | 23.9 (20.2-27.8) | .93 |
| Medical history | |||||||
| Tobacco use (cigarette) | 66 | 15 (23) | 16 | 3 (19) | 50 | 12 (24) | >.9 |
| Venous thromboembolism* | 66 | 19 (29) | 16 | 6 (38) | 50 | 13 (26) | .53 |
| Pulmonary hypertension | 66 | 14 (21) | 16 | 1 (6) | 50 | 13 (26) | .16 |
| ACS | 66 | 41 (62) | 16 | 10 (63) | 50 | 31 (62) | >.9 |
| Stroke | 66 | 12 (18) | 16 | 2 (13) | 50 | 10 (20) | .72 |
| CKD† | 66 | 23 (35) | 16 | 1 (6) | 50 | 22 (44) | .006 |
| Diabetes | 66 | 6 (9) | 16 | 1 (6) | 50 | 5 (10) | >.9 |
| Splenectomy‡ | 66 | 12 (18) | 16 | 3 (19) | 50 | 9 (18) | >.9 |
| Congestive heart failure | 66 | 10 (15) | 16 | 1 (6) | 50 | 9 (18) | .43 |
| Treatment (chronic) | |||||||
| HU | 66 | 28 (42) | 16 | 10 (63) | 50 | 18 (36) | .08 |
| Chronic transfusion | 66 | 5 (8) | 16 | 1 (6) | 50 | 4 (8) | >.9 |
| l-glutamine | 66 | 9 (14) | 16 | 3 (19) | 50 | 6 (12) | .68 |
| Crizanlizumab | 66 | 1 (2) | 16 | 0 | 50 | 1 (2) | >.9 |
| Voxelotor | 66 | 3 (5) | 16 | 1 (6) | 50 | 2 (4) | >.9 |
| Any disease modifier | 66 | 35 (53) | 16 | 11 (69) | 50 | 24 (48) | .17 |
| Characteristic . | All patients . | Not hospitalized . | Hospitalized . | P . | |||
|---|---|---|---|---|---|---|---|
| n . | Results . | n . | Results . | n . | Results . | ||
| Demographic | |||||||
| Age, median (IQR), y | 66 | 34 (24-40) | 16 | 36 (26-40) | 50 | 33 (24-40) | .72 |
| Female sex | 66 | 36 (55) | 16 | 12 (75) | 50 | 24 (48) | .084 |
| Hispanic | 66 | 10 (15) | 16 | 3 (19) | 50 | 7 (14) | .70 |
| Genotype | 66 | 16 | 50 | .79 | |||
| SS/Sβ0 | 47 (71) | 13 (81) | 34 (68) | ||||
| SC | 14 (21) | 2 (13) | 12 (24) | ||||
| Sβ+ | 5 (8) | 1(6) | 4 (8) | ||||
| BMI, median (IQR), kg/m2 | 65 | 24.3 (20.2-27.8) | 16 | 24.4 (19.2-27.2) | 49 | 23.9 (20.2-27.8) | .93 |
| Medical history | |||||||
| Tobacco use (cigarette) | 66 | 15 (23) | 16 | 3 (19) | 50 | 12 (24) | >.9 |
| Venous thromboembolism* | 66 | 19 (29) | 16 | 6 (38) | 50 | 13 (26) | .53 |
| Pulmonary hypertension | 66 | 14 (21) | 16 | 1 (6) | 50 | 13 (26) | .16 |
| ACS | 66 | 41 (62) | 16 | 10 (63) | 50 | 31 (62) | >.9 |
| Stroke | 66 | 12 (18) | 16 | 2 (13) | 50 | 10 (20) | .72 |
| CKD† | 66 | 23 (35) | 16 | 1 (6) | 50 | 22 (44) | .006 |
| Diabetes | 66 | 6 (9) | 16 | 1 (6) | 50 | 5 (10) | >.9 |
| Splenectomy‡ | 66 | 12 (18) | 16 | 3 (19) | 50 | 9 (18) | >.9 |
| Congestive heart failure | 66 | 10 (15) | 16 | 1 (6) | 50 | 9 (18) | .43 |
| Treatment (chronic) | |||||||
| HU | 66 | 28 (42) | 16 | 10 (63) | 50 | 18 (36) | .08 |
| Chronic transfusion | 66 | 5 (8) | 16 | 1 (6) | 50 | 4 (8) | >.9 |
| l-glutamine | 66 | 9 (14) | 16 | 3 (19) | 50 | 6 (12) | .68 |
| Crizanlizumab | 66 | 1 (2) | 16 | 0 | 50 | 1 (2) | >.9 |
| Voxelotor | 66 | 3 (5) | 16 | 1 (6) | 50 | 2 (4) | >.9 |
| Any disease modifier | 66 | 35 (53) | 16 | 11 (69) | 50 | 24 (48) | .17 |
Data are reported by using median (IQR) and frequency tables. Variables were compared between those patients who were hospitalized and those who were not. Results are presented as n (%) unless otherwise indicated. P values compare hospitalized with nonhospitalized patients. Bold P values indicate statistically significant results (P < .05).
BMI, body mass index.
Includes pulmonary embolism.
†Defined as a serum creatinine level >1.0 in HbSS/Sβ0 patients and >1.5 in HbSC/Sβ+ patients, and/or proteinuria.
Indicates surgical splenectomy.